News | March 20, 2025
ZIM Laboratories receives marketing authorization for Dimethyl Fumarate in Portugal
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Alkem Medtech to acquire 100% stake of Bombay Ortho
Amifampridine Tablets, 10 mg are indicated for the treatment of Lambert-Eaton myasthenic syndrome in adults and pediatric patients 6 years of age and older.
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
ANVIMO will be available in dosages of 240 mg and 480 mg
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase
Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA
USFDA inspection at Emcure Pharmaceuticals API facility
This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
Subscribe To Our Newsletter & Stay Updated
